Literature DB >> 16437135

Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.

R F Schlenk, S Fröhling, F Hartmann, J Th Fischer, A Glasmacher, F Del Valle, K Götze, C Nerl, R Schoch, H Pralle, H G Mergenthaler, M Hensel, E Koller, H Kirchen, A Matzdorff, H Salwender, H G Biedermann, S Kremers, D Haase, A Benner, K Döhner, H Döhner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16437135     DOI： 10.1038/sj.leu.2404122

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Post-remission therapy for acute myeloid leukemia.

Authors:  Richard F Schlenk
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 2.  Acute myeloid leukemia in the elderly: do we know who should be treated and how?

Authors:  Aziz Nazha; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2013-08-28

3.  Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Authors:  Raphael Itzykson; Claude Gardin; Cécile Pautas; Xavier Thomas; Pascal Turlure; Emmanuel Raffoux; Christine Terré; Pierre Fenaux; Sylvie Castaigne; Hervé Dombret; Nicolas Boissel
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

4.  Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.

Authors:  C Chandra Kumar
Journal:  Genes Cancer       Date:  2011-02

5.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

6.  GPR56 contributes to the development of acute myeloid leukemia in mice.

Authors:  D Daria; N Kirsten; A Muranyi; M Mulaw; S Ihme; A Kechter; M Hollnagel; L Bullinger; K Döhner; H Döhner; M Feuring-Buske; C Buske
Journal:  Leukemia       Date:  2016-04-11       Impact factor: 11.528

7.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

Review 8.  Acute myeloid leukemia in older adults.

Authors:  Masamitsu Yanada; Tomoki Naoe
Journal:  Int J Hematol       Date:  2012-07-13       Impact factor: 2.490

9.  A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.

Authors:  Jianmin Wang; Shuqing Lü; Jianmin Yang; Xianmin Song; Li Chen; Chongmei Huang; Jun Hou; Weiping Zhang
Journal:  J Hematol Oncol       Date:  2009-07-30       Impact factor: 17.388

10.  Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).

Authors:  Yasemin Küley-Bagheri; Karl-Anton Kreuzer; Ina Monsef; Michael Lübbert; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.